Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis
NCT04325932Phase 4Withdrawn
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2016
- Primary completion
- May 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of Human urinary kallidinogenase in intracranial atherosclerosis (ICAD), ischemic stroke, Transient Ischemic Attack (TIA), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Jan 2016; status: withdrawn.
02
Drugs
Human urinary kallidinogenase
03
Conditions
intracranial atherosclerosis (ICAD)ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT04325932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04325932.